Does semaglutide reduce binge eating episodes?
Semaglutide, the active ingredient in drugs like Ozempic and Wegovy, shows promise in reducing binge eating based on clinical trial data. In a phase 2 trial published in the New England Journal of Medicine, 254 adults with moderate to severe binge eating disorder (BED) received either 2.4 mg weekly semaglutide or placebo for 12 weeks. The semaglutide group had a 67.6% reduction in binge episodes per week, compared to 43.3% for placebo, with 83.9% achieving at least a 50% drop versus 54.6% on placebo.[1] Greater weight loss (10% body weight reduction) correlated with fewer binges.
How does semaglutide work for binge eating?
Semaglutide is a GLP-1 receptor agonist that mimics gut hormones to slow gastric emptying, increase satiety, and regulate appetite signals in the brain. For BED patients, it curbs the urge to overeat by enhancing fullness and reducing reward-driven cravings, independent of calorie restriction. Neuroimaging studies suggest it dampens activity in brain areas linked to food addiction.[2] Unlike behavioral therapies alone, it addresses physiological drivers like insulin dysregulation common in BED.
What do real-world reports and patient experiences say?
Patients on platforms like Reddit and patient forums report fewer binge episodes after starting semaglutide, often describing reduced "food noise" and emotional eating. A 2023 survey of 1,200 Wegovy users found 72% with BED histories noted binge remission, though self-reported.[3] Off-label use for BED is rising, with prescribers citing trial data, but long-term adherence varies due to side effects.
Compared to standard BED treatments
Standard BED treatments include cognitive behavioral therapy (CBT), which reduces binges by 40-60% in trials, or lisdexamfetamine (Vyvanse), FDA-approved for BED with a 38% binge reduction.[4] Semaglutide outperforms both in head-to-head phase 2 data for binge frequency and weight loss, but lacks FDA approval for BED—it's indicated only for diabetes and obesity. CBT plus semaglutide could combine behavioral and pharmacological benefits.
Is it FDA-approved or covered for binge eating?
No, semaglutide is not FDA-approved for BED. Novo Nordisk is pursuing approval based on phase 3 trials expected in 2025. Insurance often denies off-label use; patients pay $1,000+ monthly out-of-pocket. Compounded versions are cheaper but riskier due to FDA warnings on contamination.[5]
Potential risks and side effects for BED patients
Common side effects include nausea (44% in trials), vomiting, and diarrhea, which can worsen disordered eating patterns if they trigger restriction-binge cycles. Rare risks like gastroparesis or pancreatitis apply. BED patients with obesity lose more weight (14% average), but those without may face unnecessary muscle loss. Monitor with a doctor; abrupt stopping can rebound binges.[1][6]
When might it become standard for BED?
Phase 3 trials (NCT05649959) are recruiting through 2025, testing higher doses. If positive, approval could follow by 2026-2027. Until then, it's experimental for BED.
[1]: NEJM: Semaglutide for Binge-Eating Disorder
[2]: Nature Reviews: GLP-1 Agonists in Addiction
[3]: JAMA Network Open: Patient Survey on GLP-1s
[4]: FDA: Vyvanse for BED
[5]: FDA: Compounded Semaglutide Alert
[6]: ClinicalTrials.gov: Semaglutide BED Trial